Connectivity-guided accelerated theta burst stimulation as augmentation for inpatient treatment-resistant depression: a randomized, double-blind, sham-controlled trial
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Importance
Standard repetitive transcranial magnetic stimulation protocols are difficult to integrate into inpatient psychiatric care because they require daily treatment over several weeks. Accelerated intermittent theta-burst stimulation (iTBS) may offer a feasible augmentation strategy for hospitalized patients with treatment-resistant depression (TRD).
Objective
To determine whether connectivity-guided accelerated iTBS improves depressive symptoms beyond routine multimodal inpatient care in hospitalized patients with TRD.
Design, Setting, and Participants
This randomized, double-blind, sham-controlled clinical trial was conducted in the inpatient unit of the Department of Psychiatry, University of Oldenburg, Karl-Jaspers-Klinik, Bad Zwischenahn, Germany. Patients aged 18 to 65 years with unipolar TRD were recruited between May 2021 and August 2024.
Interventions
Participants received active or sham iTBS targeting an individualized left dorsolateral prefrontal cortex site showing strongest functional anticorrelation with the subgenual anterior cingulate cortex using resting-state functional MRI. Treatment was delivered as 3 daily sessions over 10 weekdays (30 sessions; 54 000 pulses total) as augmentation to routine multimodal inpatient care.
Main Outcomes and Measures
Primary and secondary outcomes were changes in Montgomery-Åsberg Depression Rating Scale (MADRS) scores assessed weekly and Beck Depression Inventory–II (BDI-II) scores assessed daily during the 2-week stimulation phase. Exploratory outcomes included response and remission rates.
Results
Of 57 randomized participants, 51 completed treatment (active, n=27; sham, n=24). The cohort exhibited moderate-to-severe treatment resistance (mean Maudsley Staging Method score, 10.9) and psychiatric comorbidity in 82% of participants. Active iTBS was associated with steeper MADRS improvement than sham (−3.54 points/week; 95% CI, −5.53 to −1.55; false discovery rate– adjusted P <.001), corresponding to model-estimated reductions of 12.06 versus 4.98 points (Cohen d = −0.89). BDI-II trajectories similarly favored active treatment, although with a smaller effect size (−0.23 points/day; 95% CI, −0.41 to −0.05; false discovery rate–adjusted P =.02; Cohen d = −0.22). MADRS response rates were higher with active iTBS (42.3% vs 13.0%), whereas remission rates were numerically but not significantly greater (26.9% vs 12.5%). No serious adverse events occurred.
Conclusions and Relevance
Accelerated connectivity-guided iTBS produced significant add-on antidepressant effects during acute inpatient treatment of TRD. Larger multicenter trials are needed to establish durability and optimize clinical implementation.
Trial Registration
ClinicalTrials.gov Identifier: NCT04832750 .
